Bronchial spasm is an uncontrollable and usually temporary contraction of the muscles in the bronchial tubes that carry air to and from the lungs. The main symptoms include shortness of breath, chest tightness, wheezing, and coughing. The use of bronchodilators and corticosteroids to relax the bronchial tubes and reduce inflammation is gaining importance in treating bronchial spasm. The global bronchial spasm therapeutics market offers products such as short-acting beta2-agonists, anticholinergics, theophylline, corticosteroids, and leukotriene antagonists. The rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) along with the side effects of long term medication have boosted the demand for safe and effective therapies.
The Global Bronchial Spasm Market is estimated to be valued at US$ 5.4 billion in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024-2030.
Key Takeaways
Key players operating in the bronchial spasm market are GlaxoSmithKline, Merck & Co, Boehringer Ingelheim, AstraZeneca, and Teva Pharmaceutical Industries.
Rising awareness regarding early treatment and management of respiratory diseases has opened up opportunities for novel therapies and drug delivery mechanisms. The market is also witnessing a lot of research into biologics, stem cell therapies, and targeted drug delivery.
The key players are focusing on geographic expansion into emerging economies of Asia Pacific, Latin America, and Middle East & Africa to tap the high undiagnosed population and growing healthcare expenditure. Global players are also actively engaging in mergers and acquisitions for new product developments.
Market Drivers
The growing pollution levels, changing lifestyles, rising smoking rates are leading to a significant rise in bronchial disorders globally. Long term exposure to environmental toxins, allergens, and particulate matter is the primary driver for bronchial spasms. Furthermore, the market is driven by increasing government support through favorable regulations on drug development and reimbursement for therapies.
Market Restraints
However, the high costs and lack of access to advanced therapeutics in low-income countries limit the overall market potential. Additionally, the complex molecular mechanisms behind respiratory diseases pose major challenges in research and development of novel treatments. Lastly, the side effects of certain commonly used bronchodilators like shortness of breath further restrain the bronchial spasm therapeutics market growth.
Segment Analysis
Short-acting bronchodilators form the largest segment in the bronchial spasm market. These drugs offer quick relief from bronchial spasms and are prescribed as the first line of treatment. They work within a few minutes and provide relief for 3-4 hours. This segment dominates as bronchial spasms require immediate relief and short-acting bronchodilators fulfill this need effectively.
Long-acting bronchodilators are the second largest segment. These drugs have a longer duration of action, around 12 hours, providing all-day relief from bronchial spasms. They are prescribed to patients who need continuous control of their condition.
Global Analysis
North America dominates the global bronchial spasm market owing to a high prevalence of respiratory disorders like asthma and COPD. According to the Centers for Disease Control and Prevention, around 26 million Americans suffer from asthma. Moreover, the region has advanced healthcare infrastructure and high awareness among people about the availability of treatment options for bronchial spasms.
Asia Pacific is expected to witness the fastest growth during the forecast period. Rapid urbanization, growing pollution levels, and adopting of sedentary lifestyle in developing countries are increasing the burden of respiratory diseases. Additionally, improved access to diagnosis and treatment in these regions will support the market expansion. China and India have a large patient pool suffering from respiratory issues offering significant untapped market potential.
What Are The Key Data Covered In This Bronchial Spasm Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bronchial Spasm ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Bronchial Spasm and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bronchial Spasm Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bronchial Spasm vendors
Writer, has a strong foothold in the market research industry. She specializes in writing well-researched
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile